On the Record · Genmab A/S
Genmab A/S competitors, on the record
The companies Genmab A/S itself names as competitors in its annual reports, 2023 to 2025, each with the sentence it appears in and the filing it came from.
Who Genmab A/S names
| Company | Named in |
|---|---|
| Abbvie | 2025 |
| AstraZeneca | 2025 |
| Bicara Therapeutics | 2025 |
| BioThera Solutions | 2025 |
| Eiasi | 2025 |
| Eli Lilly | 2025 |
| Genentech Inc. | 2025 |
| J&J | 2025 |
| Lepu Biopharma | 2025 |
| Lilly | 2025 |
| TG Therapeutics | 2025 |
In its own words
Abbvie
Word for word“With respect to Rina-S competitors, Abbvie’s ELAHERE® was the first folate receptor-alpha (FRa) targeting ADC approved, initially in the US and recently in the EU.” 20-F for 2025
AstraZeneca, BioThera Solutions, Eiasi, Eli Lilly
Word for word“We are aware of several other FRa ADCs in development, including AbbVie’s next-generation FRa ADC IMGN151; Eli Lilly’s LY4170156; AstraZeneca’s AZD5335; Eiasi’s farletuzumab; and BioThera Solutions’ BAT8006.” 20-F for 2025
Bicara Therapeutics, J&J, Lepu Biopharma
Word for word“We are aware of several next-generation EGFR-targeted approaches that could compete directly or indirectly with petosemtamab, including J& J’s RYBREVANT, Bicara Therapeutics’ BCA101, and EGFR-directed antibody–drug conjugates such as Lepu Biopharma’s MRG003 and AbbVie’s serclutamab talirine (ABBV-321).” 20-F for 2025
Genentech Inc., TG Therapeutics
Word for word“A number of companies are also working to develop potential treatments for MS that may in the future further intensify the competition in the MS market, such as TG Therapeutics’ BRIUMVI™, approved in December 2022 and Genentech Inc.’s OCREVUS ® (a CD20 antibody), approved in 2017 .” 20-F for 2025
Lilly
Word for word“With respect to petosemtamab competitors, Lilly's Erbitux ® remains the established EGFR-targeting antibody in HNSCC.” 20-F for 2025
Read from Genmab A/S’s annual reports (20-F for 2025, 20-F for 2024, 20-F for 2023) and the financial data it files with the SEC, as of 2026-02-17. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.